Amendments to the Claims

This listing of claims replaces all other listings of claims:

1 – 9. (CANCELED)

10. (CURRENTLY AMENDED) A therapeutic method comprising providing to an eye of a patient ~~an ocular~~ a physiologic ophthalmic irrigating or volume replacement solution containing at least one of a macrolide antibiotic or mycophenolic acid at a concentration in the range between about 1 ng/ml to about 200 μg/ml to provide irrigation, wash, or volume replacement further providing an anti-inflammatory effect without increased intraocular pressure ~~a therapeutic effect~~.

11. (ORIGINAL) The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid further provides at least one of an anti-inflammatory effect, an anti-cell proliferation effect, an anti-cell migration effect, an anti-angiogenesis effect, an antimicrobial effect, and an antifungal effect.

12. (CANCELED)

13. (CURRENTLY AMENDED) The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid further provides an anti-angiogenic effect in a patient with an ocular tumor, a patient with diabetes, or a patient with sickle cell anemia.

14. (ORIGINAL) The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration of about 1 μg/ml.

15. (ORIGINAL) The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration ranging from about 1 ng/ml to about 20 μg/ml.

16. (ORIGINAL) The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration ranging from about 20 μg/ml to about 200 μg/ml.

17. (ORIGINAL) A therapeutic method comprising intraocularly administering to a patient undergoing cataract surgery an ocular solution containing at least one of a macrolide antibiotic or mycophenolic acid at a concentration in the range from about 20 μg/ml to about 200 μg/ml within a lens capsule prior to insertion of a replacement intraocular lens.

18. (ORIGINAL) The method of claim 17 wherein the solution reduces opacification of the posterior capsule.

19. (ORIGINAL) The method of claim 17 wherein the macrolide antibiotic is formulated as at least one of a liposome, a macrosphere, a microsphere, a macrocapsule, a microcapsule, a macrovesicle, and a microvesicle.

20. (ORIGINAL) The method of claim 17 wherein the macrolide antibiotic or mycophenolic acid is at a concentration in the range of about 20 μg/ml to about 200 μg/ml.

21. (ORIGINAL) The method of claim 19 wherein the macrolide antibiotic or mycophenolic acid is implanted within the capsule.

22. (CURRENTLY AMENDED) An article comprising an implantable ocular replacement lens in a solution containing a concentration of a macrolide antibiotic or mycophenolic acid ranging from about 20 μg/ml to about 2000 μg/ml sufficient to provide the lens with at least one effect selected from anti-cell proliferation, anti-cell migration, anti-inflammatory, anti-angiogenesis, antimicrobial, and antifungal.

23. (CANCELED)

24. (ORIGINAL) The article of claim 22 wherein the concentration is the range between about 20 μg/ml to about 200 μg/ml.

25. (ORIGINAL) The article of claim 22 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

26. (CURRENTLY AMENDED) An article comprising an implantable ocular replacement lens containing at least one macrolide antibiotic or mycophenolic acid at a concentration ranging from about 20 µg/ml to about 2000 µg/ml.

27. (ORIGINAL) The article of claim 26 wherein the antibiotic or mycophenolic acid is in a solution in which the lens is contained.

28. (ORIGINAL) The article of claim 26 wherein the lens is a porous hydrogel and the antibiotic or mycophenolic acid is within the pores of the hydrogel lens.

29. (ORIGINAL) The article of claim 26 wherein the antibiotic or mycophenolic acid is in a coating on at least one lens surface.

30. (ORIGINAL) The article of claim 26 wherein the lens is implanted in a lens capsule and the implanted lens releases the antibiotic or mycophenolic acid in the lens capsule.

31. (ORIGINAL) The article of claim 26 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

32. (CURRENTLY AMENDED) An article comprising an implantable ocular lens in an ~~opthalmically~~ ophthalmically acceptable medium, the medium further comprising an effective anti-cell proliferative or anti-cell migratory concentration of at least one macrolide antibiotic or mycophenolic acid ranging from about 20 µg/ml to about 2000 µg/ml.

33. (CANCELED)

34. (ORIGINAL) The article of claim 32 wherein the concentration is in the range between about 200 µg/ml to about 2000 µg/ml.

35. (ORIGINAL) The article of claim 32 wherein the concentration is in the range between about 20 µg/ml to about 200 µg/ml.

36. (ORIGINAL) The article of claim 32 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.